SCHEMBL14000175

SCHEMBL14000175

Cc1ccc(N(CC(=O)Nc2ccc(-c3ncon3)cc2)C(=O)N2CCSCC2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTOR P42345 2/20 0.39
▸ PIK3CA P42336 1/20 0.39
▸ PIK3CG P48736 1/20 0.39
▸ LMNA P02545 4/20 0.36
▸ TSHR P16473 1/20 0.36
▸ HPGD P15428 2/20 0.36
▸ MAPT P10636 5/20 0.35
▸ ALDH1A1 P00352 4/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ GAA P10253 3/20 0.35
▸ MLYCD O95822 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14000176 0.84 MLYCD (0.37) MTORPIK3CAPIK3CGLMNATSHR
SCHEMBL17923455 0.84 MAPT (0.37) LMNATSHRHPGDMAPTALDH1A1
SCHEMBL14000174 0.79 MAPT (0.38) MTORPIK3CAPIK3CGLMNAHPGD
SCHEMBL3557373 0.76 MAPT (0.36) LMNAHPGDMAPTALDH1A1L3MBTL1
SCHEMBL14000170 0.75 ALDH1A1 (0.37) LMNAHPGDMAPTALDH1A1L3MBTL1
SCHEMBL17923449 0.74 SMN1; SMN2 (0.36) LMNATSHRMAPTALDH1A1L3MBTL1
SCHEMBL17923453 0.73 MAPT (0.35) LMNATSHRMAPTALDH1A1L3MBTL1
SCHEMBL14000177 0.73 WNT3A (0.36) MTORPIK3CAPIK3CGLMNATSHR
SCHEMBL3892309 0.73 NPC1 (0.37) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL6011885 0.70 NCOA3 (0.31) HPGDMAPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7465748-B2 Antiherpesvirus drugs; great pharmacokinetics, good antivirus activity when administered orally at a low dose, high safety profile, less mutagenic concerns; N-(2,6-dimethylphenyl)-N-(2-{[4-(1,3-oxazol-4-yl)phenyl]amino)-2-oxoethyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide ASTELLAS PHARMA INC. (JP) 2008-12-16 — — US disclosed
US-7465748-B2 Antiherpesvirus drugs; great pharmacokinetics, good antivirus activity when administered orally at a low dose, high safety profile, less mutagenic concerns; N-(2,6-dimethylphenyl)-N-(2-{[4-(1,3-oxazol-4-yl)phenyl]amino)-2-oxoethyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide ASTELLAS PHARMA INC. (JP) 2008-12-16 — — US disclosed
Send feedback